Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18797394 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | August 2024 | March 2025 | Allow | 7 | 1 | 1 | No | No |
| 18594132 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | March 2024 | October 2024 | Allow | 8 | 2 | 0 | No | No |
| 18410136 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | January 2024 | May 2024 | Allow | 4 | 1 | 0 | No | No |
| 18543966 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF | December 2023 | February 2025 | Abandon | 14 | 2 | 1 | No | No |
| 18449850 | TARGETED TRANS-SPLICING USING CRISPR/CAS13 | August 2023 | January 2025 | Allow | 17 | 2 | 2 | Yes | No |
| 18178841 | Oligonucleotide Comprising Inosine for Treating DMD | March 2023 | May 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18174793 | METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXBETA REDUCTASE | February 2023 | May 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18147549 | REDUCING BETA-CATENIN EXPRESSION TO POTENTIATE IMMUNOTHERAPY | December 2022 | June 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18145604 | ANTISENSE OLIGOMER COMPOUNDS | December 2022 | April 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18086209 | SIRT1-saRNA Compositions and Methods of Use | December 2022 | June 2025 | Abandon | 30 | 0 | 1 | No | No |
| 18056664 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | November 2022 | December 2024 | Allow | 25 | 2 | 0 | No | No |
| 18056382 | Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 | November 2022 | May 2025 | Abandon | 29 | 0 | 1 | No | No |
| 18053447 | Modulators of APOL1 Expression | November 2022 | August 2024 | Allow | 21 | 1 | 0 | No | No |
| 18047973 | COMPOUNDS AND METHODS FOR MODULATING ATXN1 | October 2022 | August 2024 | Allow | 22 | 1 | 0 | No | No |
| 17936820 | MICRORNA AND USES THEREOF IN PREVENTION AND/OR TREATMENT OF FIBROPLASIA MEDICAL SIGN AND/OR SYNDROME | September 2022 | June 2025 | Allow | 32 | 2 | 1 | No | No |
| 17931659 | Novel System for the Biocontrol of White Spot Syndrome Virus (WSSV) in Aquaculture | September 2022 | July 2024 | Allow | 22 | 1 | 0 | No | No |
| 17822511 | LYOPHILIZATION OF RNA | August 2022 | September 2024 | Allow | 24 | 1 | 1 | No | No |
| 17818879 | STABILIZED HNF4A SARNA COMPOSITIONS AND METHODS OF USE | August 2022 | May 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17815493 | ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF | July 2022 | August 2024 | Allow | 24 | 1 | 0 | No | No |
| 17867929 | METHODS RELATING TO LUNG CANCER | July 2022 | April 2025 | Allow | 32 | 2 | 1 | Yes | Yes |
| 17813249 | Modulation of Huntingtin Expression | July 2022 | January 2025 | Allow | 30 | 2 | 1 | No | No |
| 17811808 | DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNA | July 2022 | September 2024 | Allow | 26 | 1 | 1 | No | No |
| 17810495 | CIRCULATING MICRORNA SIGNATURES FOR OVARIAN CANCER | July 2022 | April 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17842478 | OLIGONUCLEOTIDES FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY | June 2022 | January 2025 | Allow | 31 | 2 | 1 | No | No |
| 17840152 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | June 2022 | March 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17743663 | Modified RNA Agents with Reduced Off-Target Effect | May 2022 | October 2024 | Allow | 29 | 2 | 1 | No | No |
| 17738987 | METHOD FOR DELIVERING RNA TO NEURONS TO TREAT HERPES INFECTIONS | May 2022 | July 2024 | Allow | 26 | 1 | 1 | No | No |
| 17721530 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | April 2022 | March 2025 | Allow | 35 | 1 | 1 | No | No |
| 17697577 | Modified Compounds and Uses Thereof | March 2022 | September 2024 | Allow | 30 | 1 | 1 | No | No |
| 17693120 | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR | March 2022 | August 2024 | Allow | 30 | 2 | 0 | No | No |
| 17676586 | DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNA | February 2022 | March 2024 | Allow | 25 | 1 | 0 | Yes | No |
| 17675800 | TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERS | February 2022 | July 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17667094 | MODULATORS OF MALAT1 EXPRESSION | February 2022 | August 2024 | Allow | 30 | 2 | 1 | No | No |
| 17665348 | COMPOUNDS AND METHODS FOR MODULATING C90RF72 | February 2022 | January 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17581855 | OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION | January 2022 | March 2024 | Allow | 26 | 1 | 1 | No | No |
| 17576245 | Compounds and Methods for Modulating UBE3A-ATS | January 2022 | June 2024 | Allow | 29 | 1 | 1 | No | No |
| 17537195 | BI SPECIFIC APTAMER | November 2021 | July 2024 | Allow | 32 | 2 | 1 | No | No |
| 17524323 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL | November 2021 | June 2025 | Abandon | 43 | 1 | 1 | Yes | No |
| 17523030 | CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF | November 2021 | April 2025 | Allow | 41 | 2 | 2 | Yes | No |
| 17498880 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS | October 2021 | June 2024 | Allow | 32 | 1 | 1 | No | No |
| 17478219 | THERAPEUTIC COMPOSITIONS FOR TREATING PAIN VIA MULTIPLE TARGETS | September 2021 | July 2024 | Allow | 34 | 2 | 1 | No | No |
| 17474765 | CONJUGATION OF LIPOPHILIC ALBUMIN-BINDING MOIETY TO RNA FOR IMPROVED CARRIER-FREE IN VIVO PHARMACOKINETICS AND GENE SILENCING | September 2021 | September 2024 | Allow | 36 | 2 | 1 | No | No |
| 17436254 | MULTIMERIC OLIGONUCLEOTIDES WITH ENHANCED BIOACTIVITY | September 2021 | January 2025 | Abandon | 40 | 1 | 1 | Yes | No |
| 17411460 | Treatment Of Sepsis With PCSK9 And LDLR Modulators | August 2021 | March 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17305225 | MULTIMERIC OLIGONUCLEOTIDES HAVING DECREASED KIDNEY CLEARANCE | July 2021 | December 2024 | Allow | 41 | 3 | 1 | No | No |
| 17364765 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | June 2021 | March 2025 | Allow | 45 | 4 | 1 | No | No |
| 17323826 | METHODS FOR REDUCING ATAXIN-2 EXPRESSION | May 2021 | August 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17320139 | OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULIN | May 2021 | September 2024 | Allow | 40 | 4 | 2 | Yes | No |
| 17284310 | DETECTING CANCER CELL OF ORIGIN | April 2021 | March 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17204483 | OLIGONUCLEOTIDES FOR SNCA MODULATION | March 2021 | March 2024 | Allow | 36 | 2 | 1 | No | Yes |
| 17271496 | COMPOSITIONS AND METHODS FOR DETECTING ANTIBIOTIC RESPONSIVE mRNA EXPRESSION SIGNATURES AND USES THEREOF | February 2021 | June 2025 | Allow | 52 | 2 | 1 | No | No |
| 17181870 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | February 2021 | September 2024 | Allow | 43 | 3 | 1 | Yes | No |
| 16982758 | BBB-CROSSING LIPID LIGAND OF HETERO NUCLEIC ACID | February 2021 | January 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17144456 | EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION | January 2021 | August 2024 | Allow | 43 | 2 | 1 | No | No |
| 17129463 | PLANT VIRAL RNA DELIVERY NANOPARTICLES AND USES THEREOF | December 2020 | September 2024 | Allow | 45 | 4 | 1 | No | No |
| 17055710 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | November 2020 | September 2024 | Allow | 45 | 1 | 1 | No | No |
| 17054724 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | November 2020 | December 2024 | Abandon | 49 | 2 | 2 | No | No |
| 17090804 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS ELANE GENE - II | November 2020 | June 2025 | Allow | 55 | 3 | 1 | No | No |
| 16772678 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF | September 2020 | March 2025 | Allow | 57 | 2 | 1 | Yes | No |
| 16967131 | HETEROCHIRAL NUCLEIC ACID STRAND-DISPLACEMENT SYSTEMS AND METHODS | August 2020 | October 2024 | Allow | 51 | 1 | 1 | No | No |
| 16961187 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS | July 2020 | August 2024 | Allow | 49 | 1 | 1 | No | No |
| 16955596 | DOUBLE-STRANDED DNA MOLECULE FOR THE DETECTING AND CHARACTERIZING MOLECULAR INTERACTIONS | June 2020 | July 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16875257 | ENGINEERED POST-POLY A SIGNAL RNA AND USES THEREOF | May 2020 | August 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16827454 | METHODS OF TREATING DANON DISEASE | March 2020 | June 2023 | Allow | 39 | 3 | 1 | Yes | No |
| 16638107 | CONDITIONAL-siRNAS AND USES THEREOF IN TREATING CARDIAC HYPERTROPHY | February 2020 | June 2025 | Allow | 60 | 3 | 1 | No | No |
| 16665985 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | October 2019 | January 2025 | Abandon | 60 | 1 | 1 | No | No |
| 16333185 | PROXIMITY-DEPENDENT BIOTINYLATION AND USES THEREOF | March 2019 | September 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16089190 | CONSTRUCTION OF MICRORNA GENE-MEDIATED NOVEL TISSUE ENGINEERED NERVE AND APPLICATIONS THEREOF IN REPAIRING NERVE DEFECT | September 2018 | January 2020 | Allow | 16 | 1 | 1 | No | No |
| 16046389 | ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES THEREOF IN MEDICAL FIELD | July 2018 | December 2019 | Allow | 17 | 1 | 0 | No | No |
| 15928494 | Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field | March 2018 | March 2020 | Allow | 24 | 0 | 0 | No | No |
| 15746570 | METHOD FOR MEASURING IN VIVO INHIBITION OF INTRACELLULAR RNASE | January 2018 | March 2020 | Allow | 26 | 2 | 1 | Yes | No |
| 15834110 | METHODS OF TREATING CANCER | December 2017 | September 2018 | Allow | 9 | 1 | 1 | No | No |
| 15705631 | IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT | September 2017 | July 2019 | Allow | 22 | 1 | 1 | No | No |
| 15527568 | MITOCHONDRIAL PHOSPHATE CARRIER TARGETS FOR TREATING SOFT-TISSUE CALCIFICATION | May 2017 | September 2018 | Allow | 16 | 1 | 1 | No | No |
| 15586581 | FACTOR XIA-SPECIFIC APTAMERS | May 2017 | July 2019 | Allow | 27 | 2 | 1 | No | No |
| 15519468 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT WITH A SMAD7 ANTISENSE OLIGONUCLEOTIDE | April 2017 | February 2019 | Allow | 22 | 1 | 1 | No | No |
| 15479879 | FORMULATIONS FOR THE DELIVERY OF ACTIVE INGREDIENTS | April 2017 | May 2019 | Allow | 26 | 2 | 1 | No | No |
| 15451716 | Method For Affinity Purification | March 2017 | October 2018 | Allow | 20 | 1 | 1 | No | No |
| 15433400 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | February 2017 | July 2019 | Allow | 29 | 2 | 1 | No | No |
| 15265813 | TREATMENT FOR CONDITIONS ASSOCIATED WITH FIBROSIS AND COLLAGEN DEPOSITION | September 2016 | June 2018 | Allow | 21 | 2 | 1 | Yes | No |
| 15027216 | Compositions and Methods for Treating Cancer with JAK2 Activity | April 2016 | July 2018 | Allow | 27 | 2 | 1 | No | No |
| 14996493 | Double Stranded Oligonucleotide Compounds Comprising Positional Modifications | January 2016 | June 2018 | Allow | 29 | 1 | 1 | No | No |
| 14767113 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | August 2015 | April 2019 | Allow | 44 | 3 | 1 | No | No |
| 14688499 | NUCLEIC ACIDS TARGETING TCTP FOR USE IN THE TREATMENT OF CHEMO-OR HORMONE- RESISTANT CANCERS | April 2015 | June 2018 | Allow | 38 | 6 | 1 | Yes | No |
| 13595204 | MicroRNA Fingerprints During Human Megakaryocytopoiesis | August 2012 | March 2013 | Allow | 7 | 1 | 1 | No | No |
| 13595207 | MicroRNA Fingerprints During Human Megakaryocytopoiesis | August 2012 | March 2013 | Allow | 6 | 1 | 1 | No | No |
| 13595200 | MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS | August 2012 | March 2013 | Allow | 7 | 1 | 1 | No | No |
| 13540413 | METHOD AND COMPOSITIONS INVOLVING MICRORNA | July 2012 | April 2013 | Allow | 9 | 1 | 0 | No | No |
| 13531087 | MODULATION OF FORKHEAD BOX O1A EXPRESSION | June 2012 | July 2013 | Allow | 13 | 2 | 0 | No | No |
| 13499005 | COMPOSITION FOR TREATMENT OF PANCREATIC CANCER | June 2012 | June 2013 | Allow | 14 | 1 | 1 | Yes | No |
| 13477825 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF HIF-1A EXPRESSION | May 2012 | September 2012 | Allow | 4 | 0 | 0 | No | No |
| 13365676 | SYNTHETIC MIMICS OF MIR-34 | February 2012 | August 2013 | Allow | 19 | 1 | 1 | Yes | No |
| 13380320 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFLAMMATORY DISORDERS AND FIBROTIC DISEASE | January 2012 | March 2013 | Allow | 15 | 1 | 1 | Yes | No |
| 13345893 | ANTI-MICRORNA OLIGONUCLEOTIDE MOLECULES | January 2012 | July 2012 | Allow | 6 | 0 | 0 | No | No |
| 13213390 | REDUCING IRF4, DUSP22, OR FLJ43663 POLYPEPTIDE EXPRESSION | August 2011 | November 2012 | Allow | 15 | 3 | 0 | No | No |
| 13136812 | siRNA targeting myeloid differentiation primary response gene (88) (MYD88) | August 2011 | December 2012 | Allow | 16 | 1 | 1 | No | No |
| 13169184 | MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS | June 2011 | February 2012 | Allow | 7 | 0 | 0 | No | No |
| 13139280 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER AND ASTHMA | June 2011 | November 2012 | Allow | 17 | 2 | 1 | No | No |
| 13121137 | OLIGONUCLEOTIDIC SEQUENCES ABLE TO SILENCE THE EXPRESSION OF THE CYCLIN D1-TROP2 CHIMERA AND USES THEREOF IN MEDICAL FIELD | May 2011 | April 2013 | Allow | 24 | 2 | 1 | No | No |
| 13082790 | Methods to enhance T-cell mediated immune response | April 2011 | November 2013 | Allow | 31 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHONG, KIMBERLY.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 38.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHONG, KIMBERLY works in Art Unit 1636 and has examined 232 patent applications in our dataset. With an allowance rate of 92.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner CHONG, KIMBERLY's allowance rate of 92.7% places them in the 79% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHONG, KIMBERLY receive 2.29 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CHONG, KIMBERLY is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +8.4% benefit to allowance rate for applications examined by CHONG, KIMBERLY. This interview benefit is in the 41% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 32.3% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 61.1% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 78.6% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 72.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 68.6% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 7.8% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.